Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 8/12/2019
SIETES contiene 92850 citas

 
 
 1 a 13 de 13 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Peyvandi F, Scully M, Kremer HJA, Cataland S, Knöbl P, Wu H, Antoni A, Westwood JP, Mansouri TM, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, TITAN Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016;374:511-22. [Ref.ID 100129]
2.Tiene citas relacionadas
Ponder KP. Merry Christmas for patients with hemophilia B. N Engl J Med 2011;365:2426-31. [Ref.ID 91983]
3.Tiene citas relacionadas Cita con resumen
Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CYC, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Curringham JM, Srivastava D, Basner-Tschakarjan EB, Mingozzi F, High KA, Gray JT, Reiss UM, Nenhuis AW, Davidoff AM. Adenovirus-associated virus vector - Mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65. [Ref.ID 91981]
4. Cita con resumen
Anónimo. Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther 2011;53:78-9. [Ref.ID 91712]
5.Tiene citas relacionadas
Battinelli EM. Reversal of new oral anticoagulants. Circulation 2011;124:1508-10. [Ref.ID 91689]
6.Tiene citas relacionadas Cita con resumen
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9. [Ref.ID 91688]
7.Enlace a cita originalTiene citas relacionadas
Kazmi RS, Lwaleed BA. New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol 2011;72:593-603. [Ref.ID 91566]
8.Enlace a cita originalTiene citas relacionadas
Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011;72:581-92. [Ref.ID 91565]
9.Enlace a cita originalTiene citas relacionadas
Toschi V, Lettino M. Inhibitors of propagation of coagulation: factors V and X. Eur J Clin Pharmacol 2011;72:563-80. [Ref.ID 91564]
10.Enlace a cita originalTiene citas relacionadas
Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Eur J Clin Pharmacol 2011;72:553-62. [Ref.ID 91563]
11. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
12. Cita con resumen
Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-9. [Ref.ID 82210]
13.Tiene citas relacionadas
Key NS, Negrier C. Transfusion medicine 3. Coagulation factor concentrates: past, present, and future. Lancet 2007;370:439-48. [Ref.ID 80863]
Seleccionar todas
 
 1 a 13 de 13